Skip to main content
DAIKEN logo

DAIKEN — Investor Relations & Filings

Ticker · 7780 ISIN · TW0007780009 TW Manufacturing
Open in API
Filings indexed 27 across all filing types
Latest filing 2026-05-18 Director's Dealing
Country TW Taiwan
Listing TW 7780

About DAIKEN

https://www.daikenshop.com

Daiken Biomedical Co., Ltd. (Daiken Bio) is a specialized developer of high-quality health supplements and nutritional solutions. The company utilizes a multidisciplinary research and development team comprising medical doctors, PhD experts, and nutritionists. Its product formulations are grounded in scientific evidence, drawing from thousands of international peer-reviewed journals to ensure efficacy and safety. Daiken Bio offers a diverse portfolio, including high-concentration rTG fish oil, Maca extracts, probiotics, lutein, and specialized vitamin complexes. These solutions address various health concerns such as cardiovascular support, metabolic regulation, vision health, and digestive wellness. The company emphasizes the use of internationally patented raw materials and rigorous SGS quality testing. By integrating advanced delivery technologies like slow-release systems, Daiken Bio provides targeted nutritional support for children, adults, and the elderly.

Recent filings

Filing Released Lang Actions
115年5月15日內部人設質解質
Director's Dealing Classification · 95% confidence The document is a Taiwan Market Observation Post disclosure of a share pledge by the company chairman (insider), listing pledged and released share counts. This is a personal director-level share transaction (insider dealing) rather than a corporate report. Therefore it falls under Director's Dealing (DIRS).
2026-05-18 Chinese
115年年報及股東會資料 — 2026_7780_20260604F17.pdf
Regulatory Filings Classification · 65% confidence The document is a regulatory disclosure listing the top ten shareholders, their share counts, percentages, and interrelationships. It does not present an announcement of threshold‐crossing share ownership changes, nor is it a transaction notice or a proxy statement. It serves as a compliance/regulatory filing without substantive financial statements or voting materials. This falls into the miscellaneous regulatory disclosures category (RNS).
2026-05-14 Chinese
115年年報及股東會資料 — 2025_7780_20260604FE4.pdf
Annual Report Classification · 95% confidence The document is titled “2025 Annual Report” and contains comprehensive annual report sections including a letter to shareholders, corporate governance report, funding and capitalization status, operational overview, financial analysis, and risk assessment. It provides full financial performance data and detailed narrative typical of a standalone full-year report. This matches the definition of an Annual Report (Code: 10-K). FY 2025
2026-05-14 English
115年年報及股東會資料 — 2025_7780_20260604F04.pdf
Annual Report Classification · 90% confidence The document is the company’s official annual report (“年報”) for the 114th fiscal year, complete with chairman’s letter to shareholders, corporate governance report, full financial and operational review, governance tables, and detailed disclosures. It is not merely an announcement or proxy, but the substantive annual report itself. Therefore, it matches the definition of an Annual Report (10-K). FY 2025
2026-05-14 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 75% confidence The document is titled “115年1季申報作業” and contains detailed quarterly financial schedules (investment balances, equity-method investee information) for Q1 of the ROC year 115. It presents substantive accounting data rather than merely announcing or linking to a report. This aligns with an Interim/Quarterly Report, not an announcement or standalone Excel supplement. Q1 2026
2026-05-13 Chinese
115年第1季財務報告書 — 202601_7780_AI1.pdf
Interim / Quarterly Report Classification · 94% confidence The document is a consolidated quarterly financial report covering the first quarter of fiscal years 115 and 114, including full financial statements (balance sheet, income statement, cash flows, equity changes), notes, and an independent auditor’s review (核閱報告) in accordance with IFRS 34 “Interim Financial Reporting.” This is the actual interim/quarterly financial report rather than an announcement or certification only. Therefore it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-13 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.